Atrial fibrillation in the elderly

( views:472, downloads:0 )
Author:
Roberto A.Franken(Department of Internal Medicine, Santa Casa S(a)o Paulo Medical School, R.Dr.Franco da Rocha 163/52, S(a)o Paulo 05015-040, Brazil)
Ronaldo F.Rosa(Department of Internal Medicine, Santa Casa S(a)o Paulo Medical School, R.Dr.Franco da Rocha 163/52, S(a)o Paulo 05015-040, Brazil)
Silvio CM Santos(Brazilian Society of Cardiology, Rua Padre bartolomeu Tadei 18, Santos 11035-150, Brazil)
Journal Title:
JOURNAL OF GERIATRIC CARDIOLOGY
Issue:
Volume 09, Issue 02, 2012
DOI:
10.3724/SP.J.1263.2011.12293
Key Word:
Atrial fibrillation;Heart failure;Thrombo-embolism;Treatment;Prevention

Abstract: This review discusses atrial fibrillation according to the guidelines of Brazilian Society of Cardiac Arrhythmias and the Brazilian Cardiogeriatrics Guidelines. We stress the thromboembolic burden of atrial fibrillation and discuss how to prevent it as well as the best way to conduct cases of atrial fibrillatios in the elderly, reverting the arrhythmia to sinus rhythm, or the option of heart rate control. The new methods to treat atrial fibrillation, such as radiofrequency ablation, new oral direct thrombin inhibitors and Xa factor inhibitors, as well as new antiarrhythmic drugs, are depicted.

  • [1]Flegel KM.From delirium cordis to atrial fibrillation:historical development of a disease concept.Ann Intern Med 1995;122:867–873.
  • [2]Sabeh MK,MacRae CA.The genetics of atrial fibrillation.Curr Opin Cardiol 2010,25:186–191.
  • [3]Falk RH.Atrial fibrillation.N Engl J Med 2001;344:1067–1078.
  • [4]Go AS,Hylek EM,Phillips KA,et al.Prevalence of diagnosed atrial fibrillation in Adults JAMA 2001;285:2370–2375.
  • [5]Benjamin EJ,Levy D,Vaziri SM,et al.Independent risk factors for atrial fibrillation in a population-based cohort.The Framingham Heart Study.JAMA 1994;271:840–844.
  • [6]Iguchi Y,Kimura K,Shibazaki K,et al.Annual incidence of atrial fibrillation and related factors in adults.Am J Cardiol 2010;106:1129–1133.
  • [7]Fuster V,Rydén LE,Cannon DS,et al.ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation.A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation).J Am Coll Cardiol 2006;48:854–906.
  • [8]Diretriz de Fibrila(c)(a)o Atrial da Sociedade Brasileira de Cardiologia.Arq Bras Cardiol 2003;81 (Supl VI):S1–S24.
  • [9]Fuster A,Rydén LE,Asinger RW,et al.ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation.J Am Coll Cardiol 2001;38:1266.
  • [10]Parkash R,Verma A,Tang ASL.Persistent atrial fibrillation:current approach and controversies.Curr Opin Cardiol 2010;25:1–7.
  • [11]The SOLVD investigators.Effect of Enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.N Engl J Med 1992;327:685–691.
  • [12]Carson PE,Johnson GR,Dunkman WB,et al.The influence of atrial fibrillation on prognosis in mild to moderate heart failure.The V-heft Studies.The V-heft VA Cooperative Studies Group.Circulation 1993;87:(6 Suppl):VI102–VI110.
  • [13]Cobler JL,Williams ME,Greenland P.Thyrotoxicosis in institutionalized elderly Patients with Atrial Fibrillation.Arch Intern Med 1984;144:1758–1760.
  • [14]Auer J,Scheibner P,Mische T,et al.Subclinical hyperthyroidism as a risk factor for atrial fibrillation.Am Heart J 2001;142:838–842.
  • [15]Furberg CD,Psaty BM,Manolio TA,et al.Prevalence of atrial fibrillation in elderly subjects:The Cardiovascular health study.Am J Cardiol 1994,74:236–241.
  • [16]Braunwald E.Shattuck lecture:Cardiovascular medicine at the turn of the millennium:triumphs,concerns,and opportunities.N Engl J Med 1997;337:1360–1369.
  • [17]Leonard JJ,Shaver J,Thompson M.Left atrial transport function.Trans Am Clin Climatol Assoc 1981;92:133–141.
  • [18]Rahimtoola SH,Ehsani A,Sinno MZ,et al.Left atrial transport function in myocardial infarction.Importance of its booster pump function.Am J Med 1975;59:686–694.
  • [19]Benjamin EJ,Wolf PA,D'Agostino RB,et al.Impact of atrial fibrillation on the risk of death:The framingham heart study.Circulation 1998;98:946–952.
  • [20]The solvd investigators studies of left ventricular disfunction effect of enalapril on mortality and the development of heart failure in assymptomatic patientes with reduced left ventricular ejection fraction.N Engl J Med 1992;327:685–691.
  • [21]Wolf PA,Abbot RD,Kannel WB.Atrial fibrillation as an independent risk factor for stoke.The framingham study.Stroke 1991;22:983–988.
  • [22]Predictors of thromboembolism in atrial fibrillation:I.Clinical features of patients at risk.The stroke prevention in atrial fibrillation investigators.Ann Intern Med 1992;116:1–5.
  • [23]Stollberger C,Chnupa P,Kronik G,et.al.Transesophageal echocardiography to asses embolic risk in patients with atrial fibrillation.Ann Intern Med 1998;128:630–638.
  • [24]Gage BF,Waterman AD,Shannon W,et al.Validation of clinical classification schemes for predicting stroke:results from the national registry of atrial fibrillation.JAMA 2001;285:2864–2870.
  • [25]Lip GY,Nieuwlaat R,Pisters R,et al.Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach:the euro heart survey on atrial fibrillation.Chest 2010;137:263–272.
  • [26]ACTIVE investigators.Effect of clopidogrel added to aspirin in patients with atrial fibrillation.N Eng J Med 2009;360:2066–2078.
  • [27]Healey J,Hart RG,Pogue J,et al.Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk.Stroke 2008;39:1482–1486.
  • [28]Ott A,Breteler MM,De Bruyne MC,et al.Atrial fibrillation and dementia in a population based study:The rotterdam study.Stroke 1997;28:316–321.
  • [29]Knecht S,Oelschlager C,Duning T,et al.Atrial fibrillation in stroke free patients is associated with memory impairment and hippocampal atrophy.Eur Heart J 2008;29:2125–2132.
  • [30]Miyasaka Y,Barnes ME,Petersen RC,et al.Risk of dementia in stroke-free patients diagnosed with atrial fibrillation:data from a community-based cohort.Eur Heart J 2007;28:1962–1967.
  • [31]Israel CW,Gronefeld G,Ehrlich JR,et al.Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device:Implications for optimal patient care.J Am Coll Cardiol 2004;43:47–52.
  • [32]Patten M,Maas R,Bauer P,et al.Suppression of paroxysmal atrial tachyarrhythmias-Results of the SOPAT trial.Eur Heart J 2004;25:1395–1404.
  • [33]Page RL,Tilsch TW,Conolly SJ,et al.Asymptomatic or "Silent"atrial fibrillation.frequency in untreated patients and patients receiving azimilide.Circulation 2003;107:1041–1045.
  • [34]Lanzarotti CJ,Olshansky B.Thromboembolism in chronis atrial flutter:Is the risk underestimated.J Am Coll Cardiol 1997;30:1506–1511.
  • [35]Lloyd-Jones DM,Wang TJ,Leip EP,et al.Lifetime risk for development of atrial fibrillation:The Framingham Heart Study.Circulation 2004;110:1042–1046.
  • [36]Thomas WJ,Helen P,Daniel L,et al.Obesity and the risk of new-onset atrial fibrillation.JAMA 2004;292:2471–2477.
  • [37]Alaud-din A,Meterissian S,Lisbona R,et al.Assessment of cardiac function in patients who were morbidly obese.Surgery 1990;108:809–818.
  • [38]Brugada R,Tapscott T,Czernuszewicz GZ,et al.Identification of a genetic locus for familial atrial fibrillation.N Engl J Med 1997;336:905–911.
  • [39]Chen YH,Xu SJ,Bendahhou S,et al.KCNQ1 gain-offunction mutation in familial atrial fibrillation.Science 2003;299:251–254.
  • [40]Lai LP,Su MJ,Yeh HM,et al.Association of the human mink gene 38G allele with atrial fibrillation:evidence of possible genetic control on the pathogenesis of atrial fibrillation.Am Heart J 2002;144:485–490.
  • [41]Hart RG,Benavente O,McBride R,et al.Antithrombotic therapy to prevent stroke in patients with atrial fibrillation:a meta-analysis.Ann Intern Med 1999;131:492–501.
  • [42]Hart RG,Pearce LA,Aguilar MI.Meta-analysis:antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.Ann Intern Med 2007;146:857–867.
  • [43]Corley SD,Epstein AE,DiMarco JP,et al.Relationships between sinus rhythm,treatment,and survival in the AFFIRM study.Circulation 2004;109:1509–1513.
  • [44]Hohnloser SH,Pajitnev D,Pogue J,et al.Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy:an ACTIVE W Substudy.J Am Coll Cardiol 2007;50:2156–2161.
  • [45]Albers GW,Dalen JE,Laupacis A,et al.Antithrmbotic therapy in atrial fibrillation.Chest 2001;ll9(Suppl 1):194S.
  • [46]Hylek EM,Skates SJ,Sheehan MA,et al.An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with non-rheumatic atrial fibrillation.N Engl J Med 1996;335:540–546.
  • [47]Go AS,Hylek EM,Chang Y,et al.Anticoagulation therapy for stroke prevention in atrial fibrillation:How well do randomized trials translate into clinical practice? JAMA 2003;290:2685–2692.
  • [48]Pisters R,Lane DA,Nieuwelaat R,et al.A novel userfriendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients:the Euro Heart Survey.Chest 2010;138:1093–1100.
  • [49]Fang MC,Go AS,Chang Y,et al.A new risk scheme to predict warfarin-associated hemorrhage:The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study.J Am Coll Cardiol 2011;58:395–401.
  • [50]Armaganijan L,Eikelboom J,Healey JS,et al.New pharmacotherapy for stroke prevention in atrial fibrillation.Adv Ther 2009;26:1058–1071.
  • [51]Wann S,Curtis AB,Ellenbogen KA,et al,Recommendation for emerging antithrombotic agents 2011 focused update recommendation comments.J Am Coll Cardiol 2011;57;1330–1337.
  • [52]Marcucci M,Iorio A,Nobili A,et al.Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards.Eur J Inten Med 2010;21:516–523.
  • [53]Saxonhouse SJ,Curtis AB.Risks and benefits of rate control versus maintenance of sinus rhythm.Am J Cardiol 2003;91:27D–32D.
  • [54]Denus S,Sanoski CA,Carlsson J,et al.Rate vs rhythm control in patients with atrial fibrillation:A meta-analysis.Arch Intern Med 2005;165:258–262.
  • [55]Wyse DG,Waldo AL,Dimarco JP,et al.A comparison of rate control and rhythm control in patients with atrial fibrillation.N Eng J Med 2002;347:1825–1833.
  • [56]The AFFIRM investigators.Relationships between sinus rhythm,treatment,and survival in the atrial fibrillation followup investigation of rhythm management (AFFIRM) study.Circulation 2004;109:1509–1513.
  • [57]Zimerman LI,Fenelon G,Martinelli Filho M,et al.Sociedade brasileira de cardiologia.diretrizes brasileiras de fibrila(c)(a)o atrial.Arq Bras Cardiol 2009;92(6 Supl.1):S1–S39.
  • [58]Duray GZ,Ehrlich JR,Hohnloser SH.Dronedarone:A novel antiarrhythmic agent for the treatment of atrial fibrillation.Curr Opin Cardiol 2010,25:53–58.
  • [59]Singh BN,Connolly SJ,Crijns HJ,et al.Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.N Engl J Med 2007;357:987–999.
  • [60]Touboul P,Brugada J,Capucci A,et al.Dronedarone for prevention of atrial fibrillation:A dose-ranging study.Eur Heart J 2003;24:1481–1487.
  • [61]Hohnloser SH,Crijns HJ,van Eickels M,et al.Effect of dronedarone on cardiovascular events in atrial fibrillation.N Eng J Med 2009;360:668–678.
  • [62]Wood S.Dronedarone trial suspended due to CV events in permanent atrial fibrillation Sanofi provides Multaq phase III B PALLAS trial uptodate (press release).http://www.theheart.org/ article/1251405.do (accessed on July 7,201)
  • [63]Savelieva I,Kakouros N,Kourliouros A,et al.Upstream therapies for management of atrial fibrillation:Review of clinical evidence and implications for European Society of Cardiology Guidelines.Part I:Primary prevention.Europace 2011;13:308–328.
  • [64]Fuster V,Ryden LE,Cannom DS,et al.2011 ACCF/AHA/ HRS Focused Update incorporated into the ACC/AHA/ESC 2006 Guidelines for Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline) A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.Circulation 2011;123:E269–E367.
  • [65]Camm JA,Kirchhof P,Lip GYH.et al.Guidelines for the management of atrial fibrillation the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC).Europace 2010;12:1360–1420.
  • [66]Haissaguerre M,Jais P,Shah DC,et al.Spontaneous initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins.N Engl J Med 1998;339:659–666.
  • [67]Noheria A,Kumar A,Wylie JV Jr,et al.Catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation:a systematic review.Arch Intern Med 2008;168:581–586.
  • [68]Pinter A,Dorian P.New Approaches to Atrial Fibrillation Management:Treat the Patient,not the ECG.Cardiovasc Ther 2010;5:302–310.
  • [69]Zimerman LI.,Fenelon G,Filho MM,et al.Diretrizes brasileiras de fibrila(c)(a)o atrial.Arq Bras Cardiol 2009;92(6 Supl 1):S1–S39.
  • [70]Gravina CF,Rosa RF,Franken RA,et al.Sociedade brasileira de cardiologia.II diretrizes brasileiras em cardiogeriatria.Arq Bras Cardiol 2010;95(3 Supl.2):S1–S112.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn